Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 219

1.

Interleukin-22 level is negatively correlated with neutrophil recruitment in the lungs in a Pseudomonas aeruginosa pneumonia model.

Broquet A, Jacqueline C, Davieau M, Besbes A, Roquilly A, Martin J, Caillon J, Dumoutier L, Renauld JC, Heslan M, Josien R, Asehnoune K.

Sci Rep. 2017 Sep 8;7(1):11010. doi: 10.1038/s41598-017-11518-0.

2.

IL-22 induces Reg3γ and inhibits allergic inflammation in house dust mite-induced asthma models.

Ito T, Hirose K, Saku A, Kono K, Takatori H, Tamachi T, Goto Y, Renauld JC, Kiyono H, Nakajima H.

J Exp Med. 2017 Oct 2;214(10):3037-3050. doi: 10.1084/jem.20162108. Epub 2017 Aug 15.

PMID:
28811323
3.

Can serum cytokine profile discriminate irritant-induced and allergen-induced symptoms? A cross-sectional study in workers mostly exposed to laboratory animals.

Lemaire M, Oppliger A, Hotz P, Renauld JC, Braun J, Maggi M, Barresi F, Schmid-Grendelmeier P, Huaux F, Dressel H.

Occup Environ Med. 2017 Aug;74(8):592-600. doi: 10.1136/oemed-2016-104137. Epub 2017 Apr 17.

PMID:
28416643
4.

Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation.

Martin JC, Wolk K, Bériou G, Abidi A, Witte-Händel E, Louvet C, Kokolakis G, Drujont L, Dumoutier L, Renauld JC, Sabat R, Josien R.

J Immunol. 2017 May 1;198(9):3671-3678. doi: 10.4049/jimmunol.1700021. Epub 2017 Mar 29.

PMID:
28356382
5.

Ccr6 Is Dispensable for the Development of Skin Lesions Induced by Imiquimod despite its Effect on Epidermal Homing of IL-22-Producing Cells.

Cochez PM, Michiels C, Hendrickx E, Dauguet N, Warnier G, Renauld JC, Dumoutier L.

J Invest Dermatol. 2017 May;137(5):1094-1103. doi: 10.1016/j.jid.2016.12.023. Epub 2017 Jan 20.

PMID:
28115058
6.

A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis.

Moretti S, Renga G, Oikonomou V, Galosi C, Pariano M, Iannitti RG, Borghi M, Puccetti M, De Zuani M, Pucillo CE, Paolicelli G, Zelante T, Renauld JC, Bereshchenko O, Sportoletti P, Lucidi V, Russo MC, Colombo C, Fiscarelli E, Lass-Flörl C, Majo F, Ricciotti G, Ellemunter H, Ratclif L, Talesa VN, Napolioni V, Romani L.

Nat Commun. 2017 Jan 16;8:14017. doi: 10.1038/ncomms14017.

7.

Flagellin-Mediated Protection against Intestinal Yersinia pseudotuberculosis Infection Does Not Require Interleukin-22.

Porte R, Van Maele L, Muñoz-Wolf N, Foligné B, Dumoutier L, Tabareau J, Cayet D, Gosset P, Jonckheere N, Van Seuningen I, Chabalgoity JA, Simonet M, Lamkanfi M, Renauld JC, Sirard JC, Carnoy C.

Infect Immun. 2017 Jan 26;85(2). pii: e00806-16. doi: 10.1128/IAI.00806-16. Print 2017 Feb.

8.

Corrigendum: Distinct Transcriptomic Features Are Associated with Transitional and Mature B-Cell Populations in the Mouse Spleen.

Kleiman E, Salyakina D, De Heusch M, Hoek KL, Llanes JM, Castro I, Wright JA, Clark ES, Dykxhoorn DM, Capobianco E, Takeda A, McCormack RM, Podack ER, Renauld JC, Khan WN.

Front Immunol. 2016 Jul 4;7:267. doi: 10.3389/fimmu.2016.00267. eCollection 2016.

9.

Loss of mutL homolog-1 (MLH1) expression promotes acquisition of oncogenic and inhibitor-resistant point mutations in tyrosine kinases.

Springuel L, Losdyck E, Saussoy P, Turcq B, Mahon FX, Knoops L, Renauld JC.

Cell Mol Life Sci. 2016 Dec;73(24):4739-4748. Epub 2016 Jul 19.

PMID:
27436342
10.

IL-22-induced antimicrobial peptides are key determinants of mucosal vaccine-induced protection against H. pylori in mice.

Moyat M, Bouzourene H, Ouyang W, Iovanna J, Renauld JC, Velin D.

Mucosal Immunol. 2017 Jan;10(1):271-281. doi: 10.1038/mi.2016.38. Epub 2016 May 4.

PMID:
27143303
11.

Interleukin-22 regulates antimicrobial peptide expression and keratinocyte differentiation to control Staphylococcus aureus colonization of the nasal mucosa.

Mulcahy ME, Leech JM, Renauld JC, Mills KH, McLoughlin RM.

Mucosal Immunol. 2016 Nov;9(6):1429-1441. doi: 10.1038/mi.2016.24. Epub 2016 Mar 23.

PMID:
27007677
12.

AhR modulates the IL-22-producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model.

Cochez PM, Michiels C, Hendrickx E, Van Belle AB, Lemaire MM, Dauguet N, Warnier G, de Heusch M, Togbe D, Ryffel B, Coulie PG, Renauld JC, Dumoutier L.

Eur J Immunol. 2016 Jun;46(6):1449-59. doi: 10.1002/eji.201546070.

13.

Complementarity and redundancy of IL-22-producing innate lymphoid cells.

Rankin LC, Girard-Madoux MJ, Seillet C, Mielke LA, Kerdiles Y, Fenis A, Wieduwild E, Putoczki T, Mondot S, Lantz O, Demon D, Papenfuss AT, Smyth GK, Lamkanfi M, Carotta S, Renauld JC, Shi W, Carpentier S, Soos T, Arendt C, Ugolini S, Huntington ND, Belz GT, Vivier E.

Nat Immunol. 2016 Feb;17(2):179-86. doi: 10.1038/ni.3332. Epub 2015 Nov 30.

14.

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.

Losdyck E, Hornakova T, Springuel L, Degryse S, Gielen O, Cools J, Constantinescu SN, Flex E, Tartaglia M, Renauld JC, Knoops L.

J Biol Chem. 2015 Nov 27;290(48):29022-34. doi: 10.1074/jbc.M115.670224. Epub 2015 Oct 7.

15.

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Springuel L, Renauld JC, Knoops L.

Haematologica. 2015 Oct;100(10):1240-53. doi: 10.3324/haematol.2015.132142. Review.

16.

IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis.

Martin JC, Bériou G, Heslan M, Bossard C, Jarry A, Abidi A, Hulin P, Ménoret S, Thinard R, Anegon I, Jacqueline C, Lardeux B, Halary F, Renauld JC, Bourreille A, Josien R.

Mucosal Immunol. 2016 Mar;9(2):539-49. doi: 10.1038/mi.2015.83. Epub 2015 Sep 2.

PMID:
26329427
17.

Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence.

Guillon A, Jouan Y, Brea D, Gueugnon F, Dalloneau E, Baranek T, Henry C, Morello E, Renauld JC, Pichavant M, Gosset P, Courty Y, Diot P, Si-Tahar M.

Eur Respir J. 2015 Sep;46(3):771-82. doi: 10.1183/09031936.00215114. Epub 2015 Aug 6.

18.

Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Lamarthée B, Malard F, Gamonet C, Bossard C, Couturier M, Renauld JC, Mohty M, Saas P, Gaugler B.

Mucosal Immunol. 2016 Mar;9(2):309-21. doi: 10.1038/mi.2015.61. Epub 2015 Jul 8.

PMID:
26153763
19.

Interferon-λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection.

Hernández PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, Gronke K, Ryffel B, Hoelscher C, Dumoutier L, Renauld JC, Suerbaum S, Staeheli P, Diefenbach A.

Nat Immunol. 2015 Jul;16(7):698-707. doi: 10.1038/ni.3180. Epub 2015 May 25.

20.

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Cuende J, Liénart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, Baron F, Dumoutier L, Renauld JC, De Haard H, Saunders M, Coulie PG, Lucas S.

Sci Transl Med. 2015 Apr 22;7(284):284ra56. doi: 10.1126/scitranslmed.aaa1983.

PMID:
25904740

Supplemental Content

Loading ...
Support Center